Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What CAGR And Valuation Are Anticipated For The Cardiotonic Agents Market?

In recent times, there has been a swift expansion in the cardiotonic agents market size. The market is predicted to surge from $2.78 billion in 2024 to $3.11 billion in 2025, with an impressive compound annual growth rate (CAGR) of 11.9%. Factors contributing to the growth during the historical period include a surge in heart failure cases, an elderly population on the rise, an increasing occurrence of coronary artery disease, the growing preference for passive lifestyles, and the escalating concerns of hypertension and diabetes.

The market for cardiotonic agents is predicted to experience swift expansion in the coming years, eventually amounting to “$4.95 billion in 2029” with a compound annual growth rate (CAGR) of 12.3%. The projected growth throughout this period is linked to escalating cardiovascular death rates, an increase in clinical trials concentrating on superior cardiotonic formulas, growing collaborations between public and private sectors in cardiovascular medication creation, an escalating number of hospital admissions arising from cardiac issuess, and a rising requirement for personalized cardiovascular treatments. The forecast period is set to witness the emergence of new trends which include advancement in peptide-based cardiotonic agents, the formation of dual-mechanism medications, inclusion of pharmacogenomics, innovation in injectable depot formulations, along with the creation of innovative combination therapies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24184&type=smp

Which Demand Drivers Are Strengthening The Cardiotonic Agents Market?

The increasing occurrence of cardiovascular diseases is anticipated to boost the cardiotonic agents market’s expansion. These diseases, known as cardiovascular diseases (CVDs), encompass numerous disorders affecting the heart and blood vessels, such as coronary artery disease, heart failure, arrythmias, and strokes. The surge in these conditions is largely attributed to unhealthy eating habits, high in saturated fats, trans fats, salt, and processed sugars, which lead to obesity, hypertension, and raised cholesterol levels. Cardiotonic agents are designed to enhance the heart muscle’s effectiveness and contraction strength, facilitating improved blood circulation and alleviating various cardiovascular disease symptoms. For example, the Australian Institute of Health and Welfare reported an increase in doctor-certified deaths from coronary heart disease in Australia, from 14,100 in 2021 to 14,900 in 2022. Hence, the escalating prevalence of cardiovascular diseases fuels the cardiotonic agents market’s growth.

What Is The Segment Breakdown Of The Cardiotonic Agents Market?

The cardiotonic agents market covered in this report is segmented –

1) By Drug Type: Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents, Other Drug Types

2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations

3) By Dosage Form: Tablet, Solution, Other Dosage Forms

4) By Application: Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension, Other Applications

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Digitalis Glycoside: Digoxin, Digitoxin, Lanatoside C

2) By Phosphodiesterase Inhibitors: Milrinone, Enoximone, Amrinone

3) By Cardioprotectants: Coenzyme Q10, Dexrazoxane, Trimetazidine

4) By Sympathomimetic Agents: Dobutamine, Dopamine, Norepinephrine

5) By Other Drug Types: Levosimendan, Omecamtiv Mecarbil, Cilostazol

How Are Global Trends Impacting The Development Of The Cardiotonic Agents Market?

Prominent corporations in the cardiotonic agents market are focusing their efforts on creating innovative goods, such as quick-acting inotropic medications, to boost heart function during acute heart failure and cardiogenic shock. These quick-acting inotropic drugs serve to temporarily increase the heart’s contracting ability, resulting in enhanced cardiac output. For instance, Hikma Pharmaceuticals plc, a pharmaceutical company based in the UK, introduced Dobutamine Injection, USP, in a 250 mg/20 mL vial in June 2023. This injectable drug is prescribed for temporary inotropic assistance in adults suffering from cardiac decompensation due to decreased heart contractility, frequently resulting from heart disease or post-cardiac surgery. Its working mechanism involves the stimulation of beta-1 receptors, enhancing heart muscle contractions and cardiac output swiftly within 1–2 minutes of administration. Typically administered intravenously in a hospital setup, this injection necessitates close monitoring.

Which Firms Are Driving Innovation Within The Cardiotonic Agents Market?

Major companies operating in the cardiotonic agents market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Fresenius Kabi, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Alchem International Private Ltd, Farbe Firma Private Limited, Salius Pharma Pvt. Ltd., Johnlee Pharmaceuticals Pvt. Ltd., Healthy Life Pharma Pvt Ltd, Anwita Drugs, Varion Lifesciences, Deccan Nutraceuticals Pvt. Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/cardiotonic-agents-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Cardiotonic Agents Market?

North America was the largest region in the cardiotonic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiotonic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=24184&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model